The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 17, 2024
Filed:
Mar. 31, 2022
Applicant:
Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);
Inventors:
Kevin Fitzgerald, Brookline, MA (US);
Gregory Hinkle, Plymouth, MA (US);
Timothy Ryan Mooney, Cambridge, MA (US);
Assignee:
Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 9/00 (2006.01); A61K 31/713 (2006.01); A61K 47/14 (2017.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); A61K 9/0019 (2013.01); A61K 31/713 (2013.01); A61K 47/14 (2013.01); C12N 2310/14 (2013.01); C12N 2310/3125 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/335 (2013.01); C12N 2310/351 (2013.01); C12N 2310/3515 (2013.01);
Abstract
The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting a xanthine dehydrogenase (XDH) gene, and methods of using such double stranded RNAi agents to inhibit expression of an XDH gene and methods of treating subjects having an XDH-associated disease.